Question 1

Am I eligible for this trial based on my current treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer clinical trial (NCT06411691). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of the vaccine and the immunotherapy drugs?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer clinical trial (NCT06411691). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer clinical trial (NCT06411691). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer clinical trial (NCT06411691). Contact the study team or your healthcare provider for specific answers.

Question 5

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer clinical trial (NCT06411691). Contact the study team or your healthcare provider for specific answers.

Question 6

What logistical considerations should I be aware of, such as travel for treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer clinical trial (NCT06411691). Contact the study team or your healthcare provider for specific answers.

What this study is about